A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-04958242 In Subjects With Age-Related Sensorineural Hearing Loss

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Inclusion Criteria:

• Subjects must have a current diagnosis of age related sensorineural hearing loss in the range of 30-60 dB, averaged over 2 and 4 kHz in at least one ear.
• Subjects must have symmetric hearing loss
• Subjects who can read, speak and comprehend English.

Exclusion Criteria:

• Subjects who have a history of sudden hearing loss and history or diagnosis of rapidly progressive idiopathic hearing loss
• Subjects who have hearing disorders other than age related sensorineural hearing loss
• Subjects with moderate or greater tinnitus
• Pregnant females; breastfeeding females; females of childbearing potential